Cancer treatment using quinoline-substituted compounds

TW202637179APending Publication Date: 2026-09-16TAIHO PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114149771
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-18
Filing Date
2025-12-17
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001076816_001
    Figure TWG2TA001076816_001
  • Figure TWG2TA001076816_002
    Figure TWG2TA001076816_002
  • Figure TWG2TA001076816_003
    Figure TWG2TA001076816_003
Patent Text Reader

Abstract

The problem this invention aims to solve is to provide a novel combination therapy with high antitumor efficacy and few side effects. This invention provides an antitumor agent comprising zipalertinib or a salt thereof as the active ingredient, which is used in combination with other antitumor agents administered to cancer patients, wherein the other antitumor agents are selected from at least one of the group consisting of: molecularly targeted drugs, immune checkpoint inhibitors, and antibody-drug complexes.
Need to check novelty before this filing date? Find Prior Art